Symbiotec Pharmalab Limited has fixed its initial public offering (IPO) price band between ₹938 and ₹999 per equity share, each with a face value of ₹2. The subscription for the IPO will open on August 24 and close on August 27, 2026, according to livemint.com. The company has reserved 50% of the shares for qualified institutional buyers (QIBs), 15% for non-institutional investors (NIIs), and 35% for retail investors.
The IPO process involves a three-day subscription window starting August 24, allowing investors to apply within the specified price band. Symbiotec Pharmalab has structured the share allocation to balance institutional and retail participation, with half of the shares earmarked for QIBs, reflecting a strategy to attract large investors alongside retail demand. The company’s listing is anticipated on September 1, 2026, as per the disclosed timeline.
This IPO pricing and allocation approach positions Symbiotec Pharmalab to tap into the growing pharmaceutical and healthcare market in India. The price band reflects the company’s valuation strategy amid a competitive sector where several firms have recently sought public funding. The reserved quotas for different investor categories align with regulatory norms and market practices, aiming to ensure broad-based participation and liquidity post-listing.
The IPO’s subscription period will conclude on August 27, 2026, with the final share allotment and listing scheduled for September 1, 2026. Investors will monitor subscription levels closely to gauge market response to the pricing and demand for Symbiotec Pharmalab’s shares.